Ostéogenèse imparfaite

Rauch F, Glorieux FH (2004) Osteogenesis imperfecta. Lancet 363: 1377–1385 Kuurila K, Grenman R (2004) Response to “Is it necessary to screen for hearing loss in the pediatric population with osteogenesis imperfecta?” Clin Otolaryngol Allied Sci 29(3): 287 Wong RS, Follis FM, Shively BK, Wernly JA (1995) Osteogenesis imperfecta and cardiovascular diseases. Ann Thorac Surg 60(5): 1439–1443 Favier R, Bronstein C, Forin V (2002) Coagulation screening tests in 35 children with osteogenesis imperfecta. 8th International Conference on Osteogenesis Imperfecta. Annecy 1–3 Porsborg P, Astrup D, Lund AM, Ording H (1996) Osteogenesis imperfecta and malignant hyperthermia. Is there a relationship? Anesthesia 51: 863–865 Chines A, Petersen DJ, Schranck FW, Whyte MP (1991) Hypercalciuria in children severely affected with osteogenesis imperfecta. J Pediatr 119(1): 51–57 Sawin PD, Menezes AH (1997) Basilar invagination in osteogenesis imperfecta and related osteochondrodysplasia: medical and surgical management. J Neurosurg 86: 950–960 Malmgren B, Norgren S (2002) Dental aberrations in children and adolescents with osteogenesis imperfecta. Acta Odontol Scand 60: 65–71 Kempe CH, Silverman FN, Steele BF, et al. (1984) The battered-child syndrome. JAMA 251(24): 3288–3294 Glorieux FH, Pettifor JM, Jüpner H, editors (2003) Pediatric Bone: biology and diseases. San Diego: Academic Press 401–463 Byers PH (2000) Osteogenesis imperfecta: perspectives and opportunities. Curr Opin Pediatr 12: 603–609 Rauch F, Travers R, Parfitt AM, Glorieux FH (2000) Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 26: 581–589 Pepin M, Atkinson M, Starman BJ, Byers PH (1997) Strategies and outcomes of prenatal diagnosis for osteogenesis imperfecta: a review of biochemical and molecular studies completed in 129 pregnancies. Prenat Diagn 17: 559–570 Rauch F, Glorieux FH (2005) Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long? Ann Med 37: 295–302 Forin V, Arabi A, Guigonis V, et al. (2005) Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study. Joint Bone Spine 72: 313–318 Ward LM, Glorieux FH, Rauch F, et al. (2005) A randomized placebo-controlled trial of oral alendronate children and adolescents with osteogenesis imperfecta. J Bone Miner Res 20: S1–S102 Zeitlin L, Rauch F, Plotkin H, Glorieux FH (2003) Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 111(5 Pt 1): 1030–1036 Bailey RW, Dubow HI (1981) Evolution of the concept of an extensible nail accommodating to normal longitudinal bone growth: clinical considerations and applications. Clin Orthop 159: 157–170 Janus GJ, Finidori G, Engelbert RH, et al. (2000) Operative treatment of severe scoliosis in osteogenesis imperfecta: results of 20 patients after halo traction and posterior spondylodesis with instrumentation. Eur Spine J 9: 486–491 Montpetit K, Ruck-Gibis J (2004) La réadaptation chez’ enfant atteint d’ostéogenèse imparfaite. In: Chiasson RM, Munns C, Zeitlin L, editors. Approche interdisciplinaire du traitement de l’ostéogenèse imparfaite chez l’enfant. Canada: hôpital Schriners pour enfants, ISBN 2-89602-001-2 Chevrel G, Schott AM, Fontanges E, et al. (2006) Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 21(2): 300–306 McAllion SJ, Paterson CR (1996) Causes of death in osteogenesis imperfecta. J Clin Pathol 49: 627–630